Relvar

Type: Product
Name: Relvar
First reported Sep 13 2014 - Updated Sep 13 2014 - 1 reports

Vectura Group Following A Familiar Path

Summary Vectura Group isn't well-known, but it has a broad and deep portfolio of patents and technology for the formulation, manufacture, and administration of respiratory drugs. Novartis's Ultibro and Seebri are selling well in the EU and Ultibro could ... [Published Seeking Alpha - Sep 13 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

GSK data presented at ERS demonstrate potential of blood eosinophil levels to help inform COPD treatment decisions

GSK today presented data at the European Respiratory Society (ERS) Congress that show blood eosinophil levels may help predict those patients with COPD who will have a greater reduction in exacerbation rates when receiving an inhaled corticosteroid (ICS) ... [Published Noodls - Sep 08 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

LF, OSTK, ORRF, GOL, THRX, GPN Are Seasonally Ripe To Go Up In the Next Five Weeks

(M2 PRESSWIRE via COMTEX) --BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Leapfrog Enterprises Inc (NYSE:LF), Overstock.com Inc (NASDAQ:OSTK), Orrstown Financial Services Inc (NASDAQ:ORRF), Gol Linhas Aereas Inteligentes SA (NYSE:GOL), ... [Published TradingCharts.com - Sep 08 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Human medicines European public assessment report (EPAR): Relvar Ellipta, fluticasone furoate / vilanterol, Revision: 1, Authorised

Entities: Relvar, Ellipta, Humanism
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma

BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first ... [Published PR Newswire: General Business - Jul 24 2014]
Entities: Relvar, Asthma, Experience
First reported Jul 02 2014 - Updated Jul 03 2014 - 1 reports

Theravance, Inc. Appoints Theodore J. Witek, Jr. as Senior Vice President, Corporate Partnerships, Clinical and Medical Affairs

SOUTH SAN FRANCISCO, CA--(Marketwired - Jul 2, 2014) - Theravance, Inc. (NASDAQ: THRX) ("Theravance"), A Royalty Management Company, today announced the appointment of Theodore J. Witek, Jr. as Senior Vice President Corporate Partnerships, Clinical ... [Published Marketwire - Breaking News Releases - Jul 02 2014]
First reported Jun 12 2014 - Updated Jun 13 2014 - 1 reports

Theravance, Inc. Appoints George B. Abercrombie as Senior Vice President, Corporate Partnerships, Commercial

SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 12, 2014) - Theravance, Inc. (NASDAQ: THRX) ("Theravance"), a royalty management company, today announced the appointment of George B. Abercrombie, Senior Vice President, Corporate Partnerships, Commercial. ... [Published Marketwire - Breaking News Releases - Jun 12 2014]
First reported Jun 11 2014 - Updated Jun 12 2014 - 1 reports

GSK and Theravance Announce Positive Data From Two Studies Evaluating the Efficacy and Safety of Incruse(TM) Ellipta(R) When Added to Relvar(R)/Breo(R) Ellipta(R) in Patients With COPD

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 11, 2014) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from two phase III studies, which showed that patients ... [Published Marketwire - Breaking News Releases - Jun 11 2014]
First reported May 16 2014 - Updated May 16 2014 - 1 reports

Interim Management Statement

SKYEPHARMA PLC - INTERIM MANAGEMENT STATEMENTLONDON, UK, 16 May, 2014 - Skyepharma PLC (LSE: SKP), the expert oral and inhalation drug delivery company, today publishes its for the period 1 January 2014 to 15 May 2014 and provides an update on key events ... [Published TrustNet - May 16 2014]
First reported Apr 30 2014 - Updated May 01 2014 - 1 reports

1st Quarter Results

RespiratoryQ1 2014 (£1,554 million; down 11%)Respiratory sales in the quarter declined 11% to £1,554 million.  Seretide/Advair sales were down 15% to £1,039 million, Flixotide/Flovent sales decreased 2% to £193 million and Ventolin sales grew 15% to ... [Published TrustNet - Apr 30 2014]
First reported Apr 23 2014 - Updated Apr 23 2014 - 1 reports

Welcome tonic

Towards the end of 2013 the UK’s two biggest pharmaceutical firms announced major investments in new facilities and the upgrading of existing plants.AstraZeneca in November announced it was committing £120 million to a new facility in Macclesfield, Cheshire ... [Published Engineer Online - Apr 23 2014]

Quotes

...an important role in guiding effective COPD management," said Neil Barnes , Global Franchise Medical Head of Respiratory at Glaxo in a statement. "We believe it is important that further work, including prospective studies, is undertaken to generate more evidence about the promising role of blood eosinophil levels as an indicator of response to an ICS-containing regimen.”"
Neil Barnes, Global Franchise Medical Head, Respiratory, GSK said: "COPD is a heterogeneous disease and enhancing our understanding of how individual patients respond to different treatments is critical to allow treatment to be tailored to their specific needs, with the ultimate aim of improving outcomes."
...By tracking the size and price of each montha'a "s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin."
"Completion of the Capital Raise and the repayment of all of Skyepharma's bond debt has transformed the Group's balance sheet and will enable us to invest in new products, technologies and other corporate opportunities."

More Content

All (16) | News (10) | Reports (0) | Blogs (6) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Vectura Group Following A Familiar Path [Published Seeking Alpha - Sep 13 2014]
GlaxoSmithKline : Glaxo Presents Data From Bloo... [Published 4 Traders - Sep 08 2014]
GSK data presented at ERS demonstrate potential... [Published Noodls - Sep 08 2014]
LF, OSTK, ORRF, GOL, THRX, GPN Are Seasonally R... [Published TradingCharts.com - Sep 08 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 13 2014]
Surveyed EU5 Pulmonologists Expect that Relvar,... [Published PR Newswire: General Business - Jul 24 2014]
Theravance, Inc. Appoints Theodore J. Witek, Jr... [Published Marketwire - Breaking News Releases - Jul 02 2014]
Theravance, Inc. Appoints George B. Abercrombie... [Published Marketwire - Breaking News Releases - Jun 12 2014]
GSK and Theravance Announce Positive Data From ... [Published Marketwire - Breaking News Releases - Jun 11 2014]
Interim Management Statement [Published TrustNet - May 16 2014]
1st Quarter Results [Published TrustNet - Apr 30 2014]
Welcome tonic [Published Engineer Online - Apr 23 2014]
Proposed Placing and Open Offer to Raise ?112m [Published TrustNet - Mar 31 2014]
Anoro receives Positive Opinion from the CHMP [Published Vitec Group - Mar 27 2014]
Patient Recruitment Completes in Landmark RELVA... [Published Marketwire - Breaking News Releases - Mar 13 2014]
Final Results [Published TrustNet - Feb 05 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 13 2014]
Surveyed EU5 Pulmonologists Expect that Relvar,... [Published PR Newswire: General Business - Jul 24 2014]
BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first ...
Theravance, Inc. Appoints Theodore J. Witek, Jr... [Published Marketwire - Breaking News Releases - Jul 02 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Jul 2, 2014) - Theravance, Inc. (NASDAQ: THRX) ("Theravance"), A Royalty Management Company, today announced the appointment of Theodore J. Witek, Jr. as Senior Vice President Corporate Partnerships, Clinical ...
Theravance, Inc. Appoints George B. Abercrombie... [Published Marketwire - Breaking News Releases - Jun 12 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 12, 2014) - Theravance, Inc. (NASDAQ: THRX) ("Theravance"), a royalty management company, today announced the appointment of George B. Abercrombie, Senior Vice President, Corporate Partnerships, Commercial. ...
GSK and Theravance Announce Positive Data From ... [Published Marketwire - Breaking News Releases - Jun 11 2014]
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 11, 2014) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from two phase III studies, which showed that patients ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.